Amylin Pharmaceuticals, Inc., Eli Lilly and Company's Byetta May Have Cancer Risk, FDA Says

Published: Apr 12, 2010

April 9 (Bloomberg) -- Amylin Pharmaceuticals Inc. and Eli Lilly & Co.’s long-acting Byetta may be tied to increased cancer risk, a top U.S. regulator said, raising concerns that the experimental diabetes drug may need strict warnings.

Back to news